The assessment of quercetin in patients with human T-cell lymphotropic virus type 1-associated myelopathy

Phase 3

Conditions: Human T-cell lymphotropic virus associated myelopathy.
Human T-cell lymphotropic virus associated myelopathy
G04.1

Registration Number: IRCT20210531051459N2

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 40

Inclusion Criteria

Patients with human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Conscious consent to participate in the study
Aged 18 years and older

Exclusion Criteria

Pregnancy and lactation
Diagnosis of blood diseases and blood cancers such as leukemia
Consumption of quercetin in the last three months
Crocin supplementation
Curcumin supplementation
Vitamin C supplementation
Dissatisfaction with participating in the study

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The level of Interferon-gamma cytokine. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;The level of TNF-a cytokine. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;The level of Interleukin-4 cytokine. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.

Secondary Outcome Measures